Drugs Cut Bone Loss of Hormone Therapy
Bisphosphonates Counter Side Effect of Treatment for Breast Cancer
WebMD News Archive
Dec. 14, 2007 (San Antonio) -- The bone-building drugs known as bisphosphonates can offset a side effect of hormone therapy for breast cancer -- significant bone loss that can lead to fractures, three new studies suggest.
Researchers from the Austrian Breast and Colorectal Cancer Study Group report that the drug Zometa helped to build bone in premenopausal women taking Arimidex for breast cancer. Arimidex is a hormone therapy used in breast cancer patients that helps lower estrogen levels.
U.S. researchers found that postmenopausal women taking another hormone therapy used in breast cancer patients -- Femara -- were less likely to suffer bone loss if they received concomitant treatment with Zometa.
And British researchers say the biphosphonate Actonel helped to preserve bone in women taking Arimidex.
(Are you concerned about bone loss during your breast cancer treatment? Talk about it on WebMD's Breast Cancer: Friend to Friend board.)
Hormone Therapy Causes Bone Loss
About 70% of women with breast cancer have tumors that are fueled by estrogen, making hormone therapy a cornerstone of regimens to prevent recurrences and improve survival.
Doctors have used the hormone drug tamoxifen, which deprives breast cancer cells of the estrogen they need to grow, to slow tumor growth in these women for years.
More recently, they started using the more potent hormone treatments called aromatase inhibitors to shrink tumors. The drugs block an enzyme the body uses to make estrogen, thereby slashing the body's production of estrogen altogether.
These drugs can be lifesaving, but suppressed estrogen levels increase bone turnover and accelerate bone loss, says Adam Brufsky, MD, of the University of Pittsburgh. He led the American study.
Bisphosphonates increase bone formation and decreasing bone turnover, he explains.
"Aromatase inhibitors cause bone loss and these drugs can ameliorate that loss," says Eric Winer, MD, a breast cancer specialist at the Dana-Farber Cancer Institute in Boston who wasn't involved with the work.
Zometa is approved for preventing fractures in patients with advanced bone cancer. Actonel is commonly used to prevent or treat osteoporosis in postmenopausal women.
The research was presented here at the annual San Antonio Breast Cancer Symposium.